An Overview of Corneal Collagen Cross-Linking (CXL)

摘要: Corneal collagen cross-linking (CXL) was first described over a decade ago and is now considered to be one of the most important surgical innovations modern ophthalmology. Prior its introduction, no interventions were available arrest, or slow down ectatic disease progression, with corneal transplantation required in majority cases. Unlike earlier treatments ectasias that attempted only improve consequences disease, CXL aims address biomechanical weakening itself. The long-term safety efficacy have been established several studies documented significant improvements all outcome measures (visual acuity, spherical equivalent, astigmatism, keratometric findings). emerging combination other (termed ‘CXL plus’) optimizes visual topographic outcomes. This, along expansion techniques’ indications for clinical conditions, such as microbial keratitis, highlights continuous improvement initial technique confirms wide acceptance. Overall, has already demonstrated much promise indications, representing clear example recent advances ocular therapy.